Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells-Reference-Cited by-同舟云学术

Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells

Published:2015-02 Issue:2 Volume:357 Page:520-526
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Yang Lina^ORCID,Zhou Yunjiao,Li Yinghua,Zhou Juan,Wu Yougen,Cui Yunqing,Yang Gong,Hong Yang

Funder

National Natural Science Foundation of China

Shanghai Municipal Health Bureau

Ministry of Education of China

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J. Clin,2014

2. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?;Macerelli;Lung Cancer,2014

3. Signaling to NF-kappaB;Hayden;Genes Dev,2004

4. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB;Wang;Nat. Med,1999

5. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer;Garassino;Ann. Oncol,2011

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Cancer Antioxidant Regulation System in Therapeutic Resistance;Antioxidants;2024-06-27

2. Identification of a novel prognostic signature based on vitamin metabolism clustering-related genes in lung adenocarcinoma;Translational Lung Cancer Research;2024-05

3. Bunium persicum Seeds Extract in Combination with Vincristine Mediates Apoptosis in MCF-7 Cells through Regulation of Involved Genes and Proteins Expression;Anti-Cancer Agents in Medicinal Chemistry;2024-02

4. VT204: A Potential Small Molecule Inhibitor Targeting KRASG12C Mutation for Therapeutic Intervention in Non-Small Cell Lung Cancer;Technology in Cancer Research & Treatment;2024-01

5. Mutation of TP53 Confers Ferroptosis Resistance in Lung Cancer Through the FOXM1/MEF2C Axis;The American Journal of Pathology;2023-10